Literature DB >> 34279676

Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).

Neda Alrawashdh1,2, Joann Sweasy3, Brian Erstad4, Ali McBride4, Daniel O Persky3,5, Ivo Abraham6,7.   

Abstract

In this population-based study, we used the SEER database (1985-2015) to examine survival outcomes in chronic lymphocytic leukemia (CLL) patients followed up to the era of advanced treatments including targeted therapies. Data were extracted for patients 15 years or older with a primary diagnosis of CLL. A period analysis was performed to estimate 5- and 10-year relative survival rates for patients diagnosed during different calendar periods from 1985 to 2015. A mixture cure model was used to examine long-term survivors' proportions among patients diagnosed in 1985-2015 and for two cohorts diagnosed in 2000-2003, followed up to 2012 and 2004-2007, and followed up to 2015. Cox proportional hazard modeling was used for the two cohorts to estimate hazard ratios (HRs) of death adjusted for gender and age. The 5-year and 10-year age-adjusted relative survival rate ranged between 73.7 and 89.4% and from 51.6% to "not reached," respectively, for calendar periods of 1985-1989 to 2010-2014. The long-term survivor proportions varied by age and gender from 0 to 59%. The HRs (95%CI) for the 2004-2007 cohort in comparison to the 2000-2003 cohort were 0.58 (0.43-0.78), 0.58 (0.48-0.70), 0.57 (0.49-0.0.67), 0.68 (0.54-0.85), and 0.83 (0.68-1.02) for the age categories of 45-54, 55-64, 65-74, 75-84, and ≥ 85 years, respectively. Overall, relative survival improved significantly for CLL patients diagnosed between 1985 and 2015. These improvements were markedly better following the introduction of targeted therapies.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CLL; Cured survivors; Overall survival; SEER; Survival

Year:  2021        PMID: 34279676     DOI: 10.1007/s00277-021-04600-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  40 in total

1.  Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Authors:  Tait D Shanafelt; Xin V Wang; Neil E Kay; Curtis A Hanson; Susan O'Brien; Jacqueline Barrientos; Diane F Jelinek; Esteban Braggio; Jose F Leis; Cong C Zhang; Steven E Coutre; Paul M Barr; Amanda F Cashen; Anthony R Mato; Avina K Singh; Michael P Mullane; Richard F Little; Harry Erba; Richard M Stone; Mark Litzow; Martin Tallman
Journal:  N Engl J Med       Date:  2019-08-01       Impact factor: 91.245

2.  Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Robin Foà
Journal:  Haematologica       Date:  2019-02       Impact factor: 9.941

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

Review 5.  Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

6.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

7.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Authors:  Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Gilles Salles; William G Wierda; Raquel Izumi; Veerendra Munugalavadla; Priti Patel; Min Hui Wang; Sofia Wong; John C Byrd
Journal:  Lancet       Date:  2020-04-18       Impact factor: 79.321

Review 8.  Prognostic Factors for Chronic Lymphocytic Leukemia.

Authors:  Christopher Chen; Soham Puvvada
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

9.  The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Deborah A Bowen; Chaya Venkat; Susan L Slager; Clive S Zent; Neil E Kay; Megan Reinalda; Han Tun; Jeff A Sloan; Timothy G Call
Journal:  Leuk Res       Date:  2008-07-25       Impact factor: 3.156

10.  Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; James S Blachly; Kerry A Rogers; Seema A Bhat; Mojgan Jianfar; Gerard Lozanski; David M Weiss; Barbara L Andersen; Michael Gulrajani; Melanie M Frigault; Ahmed Hamdy; Raquel Izumi; Veerendra Munugalavadla; Cheng Quah; Min-Hui Wang; John C Byrd
Journal:  Cancer Discov       Date:  2020-01-08       Impact factor: 38.272

View more
  4 in total

1.  Financial toxicity in hematological malignancies: a systematic review.

Authors:  Evguenia Ouchveridze; Rahul Banerjee; Aakash Desai; Muhammad Aziz; Wade Lee-Smith; Hira Mian; Katherine Berger; Brian McClune; Douglas Sborov; Muzaffar Qazilbash; Shaji Kumar; Ghulam Rehman Mohyuddin
Journal:  Blood Cancer J       Date:  2022-04-22       Impact factor: 9.812

Review 2.  The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Authors:  Tadeusz Robak; Magda Witkowska; Piotr Smolewski
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

3.  Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

Authors:  John F Seymour
Journal:  Blood Adv       Date:  2022-02-22

Review 4.  Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.

Authors:  Abril Adriana Arellano-Llamas; Jorge Vela-Ojeda; Alvaro Hernandez-Caballero
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.945

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.